Cargando…

The predictive role of hematologic markers in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy: a retrospective cohort study

BACKGROUND: Neoadjuvant chemoimmunotherapy is an important therapeutic modality for resectable nonsmall cell lung cancer (NSCLC). The roles of the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio, and lymphocyte-to-monocyte ratio in predicting the efficacy and prognosis of patients...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Wenliang, Ren, Siying, Yang, Lulu, Xiao, Ying, Zeng, Chao, Chen, Chen, Wu, Fang, Hu, Yan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10651234/ https://www.ncbi.nlm.nih.gov/pubmed/37578441 http://dx.doi.org/10.1097/JS9.0000000000000650

Ejemplares similares

Surgical Outcomes After Neoadjuvant Chemoimmunotherapy for Resectable Non-Small Cell Lung Cancer
por: Hu, Yan, et al.
Publicado: (2021)

Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy
por: Casarrubios, Marta, et al.
Publicado: (2022)

Perioperative Outcomes of Video-Assisted Thoracoscopic Surgery Versus Open Thoracotomy After Neoadjuvant Chemoimmunotherapy in Resectable NSCLC
por: Zhang, Baihua, et al.
Publicado: (2022)

Neoadjuvant targeted therapy for resectable EGFR-mutant non-small cell lung cancer: Current status and future considerations
por: Liu, Wenliang, et al.
Publicado: (2022)

Neoadjuvant chemoimmunotherapy in resectable stage IIIA/IIIB non-small cell lung cancer
por: Chen, Yulong, et al.
Publicado: (2021)

Blood biomarkers associated to complete pathological response on NSCLC patients treated with neoadjuvant chemoimmunotherapy included in NADIM clinical trial
por: Laza‐Briviesca, Raquel, et al.
Publicado: (2021)

Prognostic Mutational Signatures of NSCLC Patients treated with chemotherapy, immunotherapy and chemoimmunotherapy
por: Smith, Margaret R., et al.
Publicado: (2023)

Osimertinib as Neoadjuvant Therapy for Resectable Non-Small Cell Lung Cancer: A Case Series
por: Hu, Yan, et al.
Publicado: (2022)

Organ preservation strategies after neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer: a multicenter retrospective cohort study
por: Hui, Bengang, et al.
Publicado: (2023)

Neoadjuvant chemoimmunotherapy as a potential therapeutic option in NSCLC UICC stage IIIA with multilevel N2 disease
por: Menghesha, Hruy, et al.
Publicado: (2022)

Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy
por: Casarrubios, Marta, et al.
Publicado: (2021)

Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations
por: Cortellini, Alessio, et al.
Publicado: (2022)

Sleeve resection after neoadjuvant chemoimmunotherapy in the treatment of locally advanced non-small cell lung cancer
por: Dai, Jie, et al.
Publicado: (2022)

Maturation and abundance of tertiary lymphoid structures are associated with the efficacy of neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer
por: Sun, Xiaoyan, et al.
Publicado: (2022)

Pattern of tumor regression after neoadjuvant chemoimmunotherapy for esophageal squamous cell carcinoma
por: Li, Bin, et al.
Publicado: (2023)

Brief Report: Acetaminophen Reduces Neoadjuvant Chemoimmunotherapy Efficacy in Patients With NSCLC by Promoting Neutrophil Extracellular Trap Formation: Analysis From a Phase 2 Clinical Trial
por: Li, Chongwu, et al.
Publicado: (2023)

Neoadjuvant immunotherapy and chemoimmunotherapy for stage II-III muscle invasive bladder cancer
por: Chen, Hualin, et al.
Publicado: (2022)

A real‐world comparison between neoadjuvant chemoimmunotherapy and chemotherapy alone for resectable non‐small cell lung cancer
por: Zhang, Baihua, et al.
Publicado: (2022)

Safety and feasibility of robotic-assisted thoracic surgery after neoadjuvant chemoimmunotherapy in non-small cell lung cancer
por: Zeng, Jun, et al.
Publicado: (2023)

Surgical perspective in neoadjuvant chemoimmunotherapy for stage II–III non‐small cell lung cancer
por: Hong, Tao, et al.
Publicado: (2021)

Case Report: Pathological Complete Response to Neoadjuvant Alectinib in a Patient With Resectable ALK-Positive Non-Small Cell Lung Cancer
por: Hu, Yan, et al.
Publicado: (2022)

Pathologic responses to neoadjuvant chemoimmunotherapy in primary limited‐stage small‐cell lung cancer
por: Lu, Meng, et al.
Publicado: (2022)

Sleeve lobectomy after neoadjuvant chemoimmunotherapy/chemotherapy for local advanced non-small cell lung cancer
por: Liang, Hengrui, et al.
Publicado: (2021)

Important Surgical and Clinical End Points in Neoadjuvant Immunotherapy Trials in Resectable NSCLC
por: Lee, Jay M., et al.
Publicado: (2021)

Concurrent chemoradiotherapy versus radiotherapy alone after induction chemoimmunotherapy for stage III NSCLC patients who did not undergo surgery: a single institution retrospective study
por: Guan, Song, et al.
Publicado: (2023)

Case Report: Uniportal Video-Assisted Thoracoscopic Parenchymal Sparing Secondary Carinal Resection and Reconstruction for the Treatment of Tracheobronchial Mucoepidermoid Carcinoma
por: Hu, Yan, et al.
Publicado: (2022)

Evaluation of the safety and effectiveness of neoadjuvant combined chemoimmunotherapy in the treatment of locally advanced esophageal squamous cell carcinoma: a retrospective single-arm cohort study
por: Xia, Pinghui, et al.
Publicado: (2022)

Correspondence Regarding “Sleeve Lobectomy After Neoadjuvant Chemoimmunotherapy Versus Chemotherapy for Squamous Cell Lung Cancer: A Multicenter, Retrospective Study”
por: Takada, Kazuki, et al.
Publicado: (2023)

Recurrent spindle cell carcinoma of the lung successfully treated by chemoimmunotherapy
por: Akaba, Tomohiro, et al.
Publicado: (2021)

Neoadjuvant immunotherapy versus chemoimmunotherapy in non-small cell lung cancer: A protocol for systematic review and meta-analysis
por: Zhu, Qunying, et al.
Publicado: (2023)

Low neutrophil-to-lymphocyte ratio predicts overall survival benefit in advanced NSCLC patients with low PD-L1 expression and receiving chemoimmunotherapy
por: Chen, Chian-Wei, et al.
Publicado: (2023)

Neoadjuvant immunotherapy or chemoimmunotherapy in non-small cell lung cancer: a systematic review and meta-analysis
por: Jiang, Juan, et al.
Publicado: (2022)

Pathological Complete Response to Neoadjuvant Chemoimmunotherapy for Early Triple-Negative Breast Cancer: An Updated Meta-Analysis
por: Rizzo, Alessandro, et al.
Publicado: (2022)

Tumor immune microenvironment predicts the pathologic response of neoadjuvant chemoimmunotherapy in non–small‐cell lung cancer
por: Han, Rui, et al.
Publicado: (2023)

Intratumoral CD103(+)CD8(+) T cells predict response to neoadjuvant chemoimmunotherapy in advanced head and neck squamous cell carcinoma
por: Ren, Siqi, et al.
Publicado: (2023)

Deep learning for predicting major pathological response to neoadjuvant chemoimmunotherapy in non-small cell lung cancer: A multicentre study
por: She, Yunlang, et al.
Publicado: (2022)

DNA methylation profiles in chronic lymphocytic leukemia patients treated with chemoimmunotherapy
por: Tsagiopoulou, Maria, et al.
Publicado: (2019)

Robotic-assisted thoracic surgery following neoadjuvant chemoimmunotherapy in patients with stage III non-small cell lung cancer: A real-world prospective cohort study
por: Gao, Yang, et al.
Publicado: (2022)

Complete Pathological Response to Neoadjuvant Chemoimmunotherapy in a Patient With Metastatic Intrahepatic Cholangiocarcinoma With High Tumor Mutational Burden
por: Abudalou, Mohammad, et al.
Publicado: (2021)

Current and Future Role of Neoadjuvant Chemoimmunotherapy for Early Triple-Negative Breast Cancer: Which Way to Go Forward
por: Rizzo, Alessandro, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_02mffafmq6nqrj1t4jm2ne9goo